| 1 |
32096250 | Antifibrogenic effects of C-C chemokine receptor type 2 antagonist in a bleomycin-induced scleroderma model. | 2021 Jan |
2 |
| 2 |
32673071 | Chemokine Receptor 2-targeted Molecular Imaging in Pulmonary Fibrosis. A Clinical Trial. | 2021 Jan 1 |
1 |
| 3 |
32253243 | IRAK-M Regulates Monocyte Trafficking to the Lungs in Response to Bleomycin Challenge. | 2020 May 15 |
1 |
| 4 |
30470612 | Evaluation of the antifibrotic potency by knocking down SPARC, CCR2 and SMAD3. | 2018 Dec |
1 |
| 5 |
27777976 | Epithelial-macrophage interactions determine pulmonary fibrosis susceptibility in Hermansky-Pudlak syndrome. | 2016 Oct 20 |
1 |
| 6 |
24507087 | Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis. | 2014 Feb 8 |
1 |
| 7 |
15538737 | C-C chemokine receptor 2 (CCR2) deficiency improves bleomycin-induced pulmonary fibrosis by attenuation of both macrophage infiltration and production of macrophage-derived matrix metalloproteinases. | 2004 Dec |
4 |
| 8 |
12925209 | Role of monocyte chemoattractant protein-1 and its receptor,CCR-2, in the pathogenesis of bleomycin-induced scleroderma. | 2003 Sep |
3 |
| 9 |
14609568 | CC-chemokine receptor 2 required for bleomycin-induced pulmonary fibrosis. | 2003 Dec 21 |
1 |
| 10 |
11591761 | Protection from pulmonary fibrosis in the absence of CCR2 signaling. | 2001 Oct 15 |
1 |